Does c-erbB-2 expression have a role in medulloblastoma prognosis?

Indian Journal of Pathology and Microbiology

Volumn 49, Issue 4, 2006, Pages 535-539

  Bal, Munita Meenu ^a   Radotra, Bishan Das ^a   Srinivasan, Radhika ^a   Sharma, Suresh C ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

c erbB 2; c erbB 4; Medulloblastoma; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MEDULLOBLASTOMA; PROGNOSIS; PROTEIN EXPRESSION; TUMOR CELL;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MEDULLOBLASTOMA; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 33845663989     PISSN: 03774929     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Aragones MP, Magallon R, Piqueras C et al. Medulloblastoma in adulthood: Prognostic factors influencing survival and recurrence. Acta Neurochir (Wien) 1994; 127:65-8.
2. Caputy A J, McCullough D C, Manz H J et al. A review of the factors influencing the prognosis of medulloblastoma. The importance of cell differentiation. J Neurosurg 1987; 66:80-7.
3. Maleci A, Cervoni L and Delfini R. Medulloblastoma in children and adults: a comparative study. Acta Neurochir (Wien) 1992; 119:62-7.
4. Muller W, Afra D, Schroder R et al. Medulloblastomas survey of factors possibly influencing the prognosis. Acta Neurochir (Wien) 1982; 64:215-24.
5. Packer RJ, Sutton LN, Rorke LB et al. Prognostic importance of cellular differentiation in medulloblastoma of childhood. J Neurosurg 1984; 61:296-301.
6. Schofield D E, Yunis E J, Geyer J R et al. DNA control and other prognostic features in childhood medulloblastoma. Proposal of a scoring system. Cancer 1992; 69:1307-14.
7. Zerbini C, Gelber R D, Weinberg D et al. Prognostic factors in Medulloblastoma, Including DNA ploidy. J Clin Oncol 1993; 11:616-22.
8. Batra SK, Rasheed BKA, Bigner SH et al. Biology of disease: oncogenes and antioncogenes in human central nervous system tumours. Lab Invest 1994; 71:621-37.
9. Jaros E, Lunec J, Perry R H, et al. p53 overexpression identifies a group of central primitive neuroectodermal tumours with poor prognosis. Br J Cancer 1993; 68:801-7.
10. Gilbertson RJ, Jaros E, Perry RH et al. Prognostic significance of the c-erb B-2 oncogene product in childhood medulloblastoma. Br J Cancer 1995; 71:473-77.
11. Gilbertson R J, Perry R H, Kelly P J et al. Prognostic significance of HER2 and HER4 coexpression on childhood medulloblastoma. Cancer Res 1997; 57:3272-80.
12. Gilbertson R, Wickramasinghe C, Hernan R et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 2001; 85:705-12.
13. Herms J. W, Behenke J, Bergmann M. et al. Potential prognostic value of c-erb B-2 expression in medulloblastomas in very young children. J Pediatr Hematol Oncol 1997; 19:510-15.
14. Gajjar A, Hernan R, Kocak M et al. Clinical, histopathologic and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 2004; 22:971-4.
15. Nam D H, Wang K C, Kim Y M et al. The effect of isochromosome 17q presence, proliferative and apoptotic indices, expression of c-erb B-2, bcl-2 and p53 proteins on the prognosis of medulloblastoma. J Korean Med Sci 2000; 15:452-6.
16. Cobleigh M A, Vogel C L, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti HER 2 monoclonal antibody in women who have HER 2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-48.
17. Gullick W J, Venter D J. The c-erb B2 and its expression in human cancer. The Molecular Biology of Cancer: Sikora K and Waxman J(eds.) p 38. Blackwell: Oxford.
18. Semba K, Kamata N, Toyoshima K et al. A v-erb B related proto-oncogene c-erb B2, is distinct from the c-erbB-1/epidermal growth factor receptor gene and is amplified in human salivary gland adenocarcinomas. Proc Natl Acad Sci 1985; 82:6497-6501.
19. Tal M, Wetzler M, Josefberg Z et al. Sporadic amplification of the HER2/neu proto-oncogene in adenocarcinoma of various tissues. Cancer Res 1988; 48:1517-21.
20. Yasin W, Yoshida K, Meda U et al. Expression of ERBB-2 in human gastric carcinoma: relationship between p185 expression and the gene amplification. Cancer Res 1990; 50:8002-9.
21. Yokota J, Yamamoto T, Toyshima K et al. Amplification of c-erb B-2 in human adenocarcinomas in vivo. Lancet 1986; 1:765-6.
22. Schechter A L, Stern D F, Vaidyanathan L. et al. The neuoncogene: an erb B-related gene encoding a 185,000- Mr tumour antigen. Nature 1984; 312:513-6.
23. Biegel J A, Rorke L B, Packer R J et al. Isochromosome 17q in primitive neuroectodermal tumours of the central nervous system. Genes Chromosomes Cancer 1989; 1:139-47.
24. Fukushige S, Matasubara K, Yoshida M et al. Localization of novel v-erbB related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 1986; 6:955-8.
25. Gassmann M, Casagranda F, Orioli D et al. Aberrant neural and cardiac development in mice lacking the Erb B4 neuregulin receptor. Nature 1995; 378:390-4.
26. Lee K F, Simon H, Chen H et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995; 378:334-5.
27. Bal M M, Radotra B D, Srinivasan R and Sharma S C. Expression of c-erbB-4 in medulloblastoma and its correlation with prognosis. Histopathology 2006; 49:92-3.
28. Gilbertson R J, Clifford S C, MacMeekin W. et al. Expression of the ErbB-Neuregulin signaling network during human cerebellar development: Implications for the biology of medulloblastoma. Cancer Res 1998; 58:3932-41.
29. Hernan R, Fasheh R, Calabrese C. et al. ERBB2 upregulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 2003; 63:140-8.